These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 1808338)

  • 41. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 44. Recombinant erythropoietin for the anemia of chronic renal failure.
    Ahmad R; Hand M
    N Engl J Med; 1987 Jul; 317(3):169-70. PubMed ID: 3600706
    [No Abstract]   [Full Text] [Related]  

  • 45. Erythropoietin for anemia of renal failure in sickle cell disease.
    Steinberg MH
    N Engl J Med; 1991 May; 324(19):1369-70. PubMed ID: 1759999
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
    Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
    Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The significance of erythropoietin for nephrology].
    Watzinger U; Peer G; Barnas U; Mayer G; Luger A; Kovarik J; Graf H
    Wien Klin Wochenschr; 1990 Mar; 102(5):125-30. PubMed ID: 2181782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis.
    Tomura S; Nakamura Y; Tachibana K; Deguchi F; Ando R; Chida Y; Marumo F
    Blood Purif; 1993; 11(6):370-7. PubMed ID: 8043258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin.
    Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA
    Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients].
    Takayama K
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):179-88. PubMed ID: 8315881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin.
    Jones MA; Kingswood JC; Dallyn PE; Sharpstone P
    Clin Exp Hypertens; 1996 Jan; 18(1):51-64. PubMed ID: 8822233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of polytransfused hemodialysis patients with recombinant human erythropoietin.
    Bommer J; Huber W; Tewes G; Ritz E; von Wedel S; Küppers S; Weinreich T; Bommer G
    Contrib Nephrol; 1988; 66():131-8. PubMed ID: 3391027
    [No Abstract]   [Full Text] [Related]  

  • 53. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin.
    Verbeelen D; Bossuyt A; Smitz J; Herman A; Dratwa M; Jonckheer MH
    Clin Nephrol; 1989 Jan; 31(1):6-11. PubMed ID: 2914412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group.
    Am J Nephrol; 1991; 11(1):23-6. PubMed ID: 2048574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin.
    Kamata K; Marumo F; Onoyama K
    Jpn Circ J; 1991 Jul; 55(7):649-56. PubMed ID: 1880896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Revolution in the treatment of chronic renal insufficiency anemia: the role of recombinant erythropoietin].
    Panas N; Turkowa M; Zgheib A; Krzesinski JM; Rorive G
    Rev Med Liege; 1990 Jun; 45(6):280-5. PubMed ID: 2367758
    [No Abstract]   [Full Text] [Related]  

  • 57. Changes in endocrinological functions in hemodialysis patients associated with improvements in anemia after recombinant human erythropoietin therapy.
    Akizawa T; Kinugasa E; Nakayama F; Takahashi T; Koshikawa S; Shimizu N
    Contrib Nephrol; 1990; 82():86-93. PubMed ID: 2093532
    [No Abstract]   [Full Text] [Related]  

  • 58. [Recombinant human erythropoietin and torasemide--innovations in nephrology].
    Internist (Berl); 1989 Mar; 30(3):220. PubMed ID: 2654065
    [No Abstract]   [Full Text] [Related]  

  • 59. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
    Frei U; Nonnast-Daniel B; Schäffer J; Koch KM
    Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
    Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
    Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.